What Clinicians Need to Know About the Development of Long-Acting Formulations-Reference-Cited by-同舟云学术

What Clinicians Need to Know About the Development of Long-Acting Formulations

Published:2022-11-21 Issue:Supplement_4 Volume:75 Page:S487-S489
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Flexner Charles¹²,Thomas David L²,Clayden Polly³,Swindells Susan⁴

Affiliation:

1. Divisions of Clinical Pharmacology, School of Medicine and Bloomberg School of Public Health, Johns Hopkins University , Baltimore, Maryland , USA

2. Infectious Diseases, School of Medicine and Bloomberg School of Public Health, Johns Hopkins University , Baltimore, Maryland , USA

3. HIV i-Base , London , United Kingdom

4. University of Nebraska Medical Center , Omaha, Nebraska , USA

Abstract

We encourage readers of this Supplement to find articles that are relevant to the current and future practice of infectious diseases medicine. Access to long-acting products and formulations in low- and middle-income countries remains a key determinant of the impact of these advances on global health.

Funder

NIH

National Institute of Allergy and Infectious Diseases

Long-Acting/Extended Release Antiretroviral Research Resource Program

Johns Hopkins University

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/article-pdf/75/Supplement_4/S487/49279002/ciac749.pdf

Reference12 articles.

1. Prolonged blood concentrations of penicillin following intramuscular benzathine penicillin G;Putnam;Antibiot Chemother (Northfield),1954

2. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy;Owen;Adv Drug Deliv Rev,2016

3. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial;Carrat;JAMA,2004

4. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression;Swindells;N Engl J Med,2020

5. Cabotegravir for HIV prevention in cisgender men and transgender women;Landovitz;N Eng J Med,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing Toward a Human Immunodeficiency Virus Cure;Infectious Disease Clinics of North America;2024-09

2. Physiologically based Pharmacokinetic Model Validated to Enable Predictions Of Multiple Drugs in a Long-acting Drug-combination Nano-Particles (DcNP): Confirmation with 3 HIV Drugs, Lopinavir, Ritonavir, and Tenofovir in DcNP Products;Journal of Pharmaceutical Sciences;2024-06

3. Preferences and feasibility of long‐acting technologies for treatment of hepatitis C virus in low‐ and middle‐income countries: A survey of providers and policymakers;Journal of Viral Hepatitis;2024-03-28

4. The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch;Current HIV/AIDS Reports;2023-09-21

5. Voluntary licensing of long‐acting HIV prevention and treatment regimens: using a proven collaboration‐ and competition‐based mechanism to rapidly expand at‐scale, sustainable, quality‐assured and affordable supplies in LMICs;Journal of the International AIDS Society;2023-07